Easy Bio Q1 Earnings Strong, Dividend Increase and M&A Growth Continue

1Q 2026 consolidated revenue 130.7 billion KRW (up 11.8% YoY), operating profit 13.2 billion (up 45%), net profit 11.7 billion (up 109%).
EPS 338 won (vs 168 won).
Cash dividend of 250 won per share (vs 200 won).
Goodwill increased by 16.49 billion due to acquisitions of BioMatrix and Nutribins, intangible assets also increased.
Debt ratio rose to 200.8% (from 188.4%), financial leverage expanded.
Foreign exchange gain of 3.86 billion, exposure to currency volatility.
R&D expenses 997 million (0.76% of revenue), slight increase.